Furthermore, the SELECT trial10 showed that semaglutide reduced major adverse CV events (MACE) in individuals with overweight or obesity without diabetes.10 These findings suggest a potential interaction between BMI and the cardioprotective effects of GLP-1 RAs. Here, GLP1R is linked to Obesity.